by Truveta staff | May 17, 2023 | News
We are excited to announce the expansion of the Truveta community to include new life science partners, including Reprieve Cardiovascular and SK Life Science, joining previously announced pioneers Pfizer, Boston Scientific Corporation, and Alpine Immune Sciences. We...
by Truveta Research | May 11, 2023 | News, Research
Today Truveta announced a new research letter published in JAMA Network Open using de-identified patient data from Truveta Studio. Published in collaboration with Anupam B. Jena, MD, PhD and Christopher M Worsham, MD, MPH from Harvard University, the new research...
by Truveta staff | May 4, 2023 | News
This post is authored by Tricia Rodriguez, senior applied scientist, Truveta Research. The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is gearing up for a fantastic event, slated for May 7-10, 2023, in Boston. As an applied scientist with...
by Terry Myerson, CEO | Apr 12, 2023 | News, Technology
UPDATE: Truveta has won the 2024 South by Southwest (SXSW) Innovation Award in Artificial Intelligence for its AI-enabled health research and the Truveta Language Model (TLM). Healthcare data traditionally has been siloed, inaccessible, and too messy to be useful for...
by Truveta staff | Mar 22, 2023 | News
Today, Truveta and Alpine Immune Sciences, Inc. announced a strategic partnership to help accelerate clinical trial recruitment for povetacicept, Alpine’s dual B cell cytokine antagonist being developed for multiple B cell-mediated autoimmune and inflammatory...
by Terry Myerson, CEO | Mar 1, 2023 | News
Today we are excited to announce that we’ve expanded the de-identified data in Truveta Studio to include 28 additional social drivers of health (SDOH) attributes – such as education, income, housing stability, social support, and more – for nearly 80 million...
